JP2011500842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500842A5 JP2011500842A5 JP2010531272A JP2010531272A JP2011500842A5 JP 2011500842 A5 JP2011500842 A5 JP 2011500842A5 JP 2010531272 A JP2010531272 A JP 2010531272A JP 2010531272 A JP2010531272 A JP 2010531272A JP 2011500842 A5 JP2011500842 A5 JP 2011500842A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- therapeutic agent
- complex
- pegylated
- ddd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- 108010011122 A Kinase Anchor Proteins Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 4
- -1 IL-I Proteins 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 102000055207 HMGB1 Human genes 0.000 claims 2
- 108700010013 HMGB1 Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 claims 1
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 101800003050 Interleukin-16 Proteins 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108050009288 Interleukin-19 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 1
- 102000034655 MIF Human genes 0.000 claims 1
- 108060004872 MIF Proteins 0.000 claims 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 1
- 102000004140 Oncostatin M Human genes 0.000 claims 1
- 108090000630 Oncostatin M Proteins 0.000 claims 1
- 108010082093 Placenta Growth Factor Proteins 0.000 claims 1
- 102100035194 Placenta growth factor Human genes 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 108700014844 flt3 ligand Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000003032 molecular docking Methods 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/925,408 US7666400B2 (en) | 2005-04-06 | 2007-10-26 | PEGylation by the dock and lock (DNL) technique |
| US11/925,408 | 2007-10-26 | ||
| PCT/US2008/081085 WO2009055653A1 (en) | 2007-10-26 | 2008-10-24 | Pegylation by the dock and lock (dnl) technique |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040570A Division JP5779789B2 (ja) | 2007-10-26 | 2014-03-03 | ドック・ロック（ｄｎｌ）技術によるｐｅｇ化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500842A JP2011500842A (ja) | 2011-01-06 |
| JP2011500842A5 true JP2011500842A5 (cg-RX-API-DMAC10.html) | 2011-12-08 |
| JP5577558B2 JP5577558B2 (ja) | 2014-08-27 |
Family
ID=40580038
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531272A Active JP5577558B2 (ja) | 2007-10-26 | 2008-10-24 | ドック・ロック（ｄｎｌ）技術によるｐｅｇ化 |
| JP2014040570A Active JP5779789B2 (ja) | 2007-10-26 | 2014-03-03 | ドック・ロック（ｄｎｌ）技術によるｐｅｇ化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014040570A Active JP5779789B2 (ja) | 2007-10-26 | 2014-03-03 | ドック・ロック（ｄｎｌ）技術によるｐｅｇ化 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7666400B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2197468B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5577558B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR101583388B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN101951939B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2008316741B9 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2696160C (cg-RX-API-DMAC10.html) |
| IL (1) | IL204066A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2010004547A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009055653A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US20110064754A1 (en) * | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US8003111B2 (en) * | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| CN101171034B (zh) | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| US20080171067A1 (en) * | 2007-01-17 | 2008-07-17 | Immunomedics, Inc. | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
| US8158129B2 (en) * | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US9931413B2 (en) | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| WO2012024223A2 (en) * | 2010-08-17 | 2012-02-23 | Immunomedics, Inc. | Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| US20100268055A1 (en) * | 2007-07-19 | 2010-10-21 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Self-Anchoring MEMS Intrafascicular Neural Electrode |
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| WO2010022225A1 (en) * | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
| ES2957546T3 (es) | 2008-12-17 | 2024-01-22 | Merck Sharp & Dohme | Producción de mono- y di-PEG-IL10; y usos |
| US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| CA2771999A1 (en) * | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| EP2473187A4 (en) * | 2009-08-31 | 2015-09-16 | Immunomedics Inc | COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY |
| CA2772572A1 (en) * | 2009-08-31 | 2011-03-03 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| WO2011034660A1 (en) * | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| IN2012DN02692A (cg-RX-API-DMAC10.html) * | 2009-11-05 | 2015-09-04 | Ct Molecular Med & Immunology | |
| IN2012DN03354A (cg-RX-API-DMAC10.html) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
| EP2509629A4 (en) * | 2009-12-09 | 2013-06-26 | Ibc Pharmaceuticals Inc | DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION |
| CN102665757A (zh) * | 2009-12-09 | 2012-09-12 | 免疫医疗公司 | 通过双特异性抗体预靶向的用于细胞毒性药物的递送系统 |
| US10822396B2 (en) | 2009-12-15 | 2020-11-03 | MuHyeon CHOE | Repeat-chain for the production of dimer, multimer, multimer complex and super-complex |
| US20120259099A1 (en) * | 2009-12-15 | 2012-10-11 | MuHyeon CHOE | Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| EP2635300A4 (en) * | 2010-11-03 | 2014-04-02 | Ibc Pharmaceuticals Inc | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) |
| EP2693887B1 (en) | 2011-04-06 | 2020-10-28 | The Board of Regents of the University of Texas System | Modulating bacterial mam polypeptides in pathogenic disease |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20130101664A1 (en) | 2011-08-18 | 2013-04-25 | Donald W. Kufe | Muc1 ligand traps for use in treating cancers |
| EP2753644A1 (en) | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
| EP2785382B1 (en) * | 2011-12-02 | 2019-01-02 | IBC Pharmaceuticals, Inc. | Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| CN104363919A (zh) | 2012-06-01 | 2015-02-18 | Ibc药品公司 | 具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物 |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US10131712B2 (en) | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| KR101358330B1 (ko) | 2012-09-26 | 2014-02-12 | 현대모비스 주식회사 | 차속 제어 장치, 이를 포함하는 차속 제어 시스템 및 그 제어 방법 |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| US9789156B2 (en) | 2013-03-11 | 2017-10-17 | Dana-Farber Cancer Institute, Inc. | Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics |
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| CA2914837A1 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US10010588B2 (en) | 2013-08-30 | 2018-07-03 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating hyperlipidemia |
| CA2924520C (en) | 2013-11-01 | 2023-09-26 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| KR20160079114A (ko) | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
| JP2017509587A (ja) | 2013-12-27 | 2017-04-06 | ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． | エトキシル化界面活性剤 |
| US10605810B2 (en) * | 2013-12-30 | 2020-03-31 | University-Industry Cooperation Group Of Kyung Hee University | Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| ES2978993T3 (es) | 2014-02-21 | 2024-09-23 | Ibc Pharmaceuticals Inc | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| EP3206713A4 (en) | 2014-10-14 | 2018-06-27 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| IL254389B2 (en) * | 2015-03-11 | 2023-03-01 | Nektar Therapeutics | Polymer conjugates and the il–7 group |
| EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| CN107614515B (zh) | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体 |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| UA126016C2 (uk) | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| CA2995120A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP7299021B2 (ja) | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン／受容体ペア |
| US10669338B2 (en) | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| WO2018027223A1 (en) | 2016-08-05 | 2018-02-08 | Duke University | Camkk2 inhibitor compositions and methods of using the same |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| CA3044082A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN107118269B (zh) * | 2017-06-05 | 2020-12-01 | 北京交通大学 | 一种重组人il-24蛋白的peg修饰方法 |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
| US12037382B2 (en) | 2018-02-05 | 2024-07-16 | Stichting Vu | Inverse agonistic anti-US28 antibodies |
| WO2019183131A1 (en) | 2018-03-19 | 2019-09-26 | Bioventures, Llc | Periostin antibodies and methods of using the same |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| US12128099B2 (en) | 2018-05-25 | 2024-10-29 | Bioventures, Llc | Myxoma virus compositions and methods of use |
| WO2020080941A1 (en) | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| US12428626B2 (en) | 2018-11-20 | 2025-09-30 | Bioventures, Llc | Cells for the production of viruses and methods of using the same |
| EP4004037A1 (en) | 2019-07-26 | 2022-06-01 | Vanderbilt University | Human monoclonal antibodies to enterovirus d68 |
| KR20220140568A (ko) | 2020-02-11 | 2022-10-18 | 벤더르빌트 유니버시티 | 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체 |
| WO2021195385A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) |
| WO2021195418A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| US20250084155A1 (en) | 2021-09-29 | 2025-03-13 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
| GB202204813D0 (en) | 2022-04-01 | 2022-05-18 | Bradcode Ltd | Human monoclonal antibodies and methods of use thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
| NL8501219A (nl) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | Immunologisch complex, de bereiding en toepassing daarvan. |
| US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5770198A (en) * | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| US20040018587A1 (en) * | 1994-10-13 | 2004-01-29 | Lee Makowski | Nanostructures containing antibody assembly units |
| US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
| US5871945A (en) | 1994-11-23 | 1999-02-16 | Icos Corporation | Modulators of anchoring protein function |
| EP1731174A3 (en) * | 1996-08-02 | 2007-01-17 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond |
| US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US6756039B1 (en) | 1999-05-10 | 2004-06-29 | The Regents Of The University Of California | Self assembling proteins |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US7060506B2 (en) * | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
| US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| CA2484676A1 (en) * | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
| US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| GEP20084486B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| US20050003403A1 (en) * | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
| US8491914B2 (en) | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US20110064754A1 (en) | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
| US8003111B2 (en) * | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
| US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
| CN101171034B (zh) * | 2005-03-03 | 2014-06-18 | 免疫医疗公司 | 人源化l243抗体 |
| US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
| US20120276100A1 (en) | 2005-04-06 | 2012-11-01 | Ibc Pharmaceuticals, Inc. | Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity |
| US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| US8067006B2 (en) * | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8158129B2 (en) | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
| CA2607056C (en) | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| CN105709237A (zh) | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
| WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2010022225A1 (en) | 2008-08-20 | 2010-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (dnl) vaccines for cancer therapy |
-
2007
- 2007-10-26 US US11/925,408 patent/US7666400B2/en not_active Expired - Lifetime
-
2008
- 2008-10-24 WO PCT/US2008/081085 patent/WO2009055653A1/en not_active Ceased
- 2008-10-24 EP EP08842661.4A patent/EP2197468B1/en not_active Not-in-force
- 2008-10-24 MX MX2010004547A patent/MX2010004547A/es active IP Right Grant
- 2008-10-24 JP JP2010531272A patent/JP5577558B2/ja active Active
- 2008-10-24 AU AU2008316741A patent/AU2008316741B9/en not_active Ceased
- 2008-10-24 CN CN2008801133361A patent/CN101951939B/zh active Active
- 2008-10-24 KR KR1020107009090A patent/KR101583388B1/ko active Active
- 2008-10-24 CA CA2696160A patent/CA2696160C/en active Active
-
2009
- 2009-12-22 US US12/644,146 patent/US7981398B2/en not_active Expired - Lifetime
-
2010
- 2010-02-21 IL IL204066A patent/IL204066A/en active IP Right Grant
-
2011
- 2011-06-01 US US13/150,613 patent/US8277817B2/en not_active Expired - Lifetime
-
2012
- 2012-08-20 US US13/589,575 patent/US9457100B2/en not_active Expired - Lifetime
-
2014
- 2014-03-03 JP JP2014040570A patent/JP5779789B2/ja active Active
-
2016
- 2016-08-25 US US15/247,386 patent/US9872920B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hogan et al. | Needle-free delivery of macromolecules through the skin using controllable jet injectors | |
| JP2006141398A5 (cg-RX-API-DMAC10.html) | ||
| Li et al. | Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy | |
| JP2012504959A5 (cg-RX-API-DMAC10.html) | ||
| JP2016025858A5 (cg-RX-API-DMAC10.html) | ||
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| JP2018514199A5 (cg-RX-API-DMAC10.html) | ||
| EP3799880A3 (en) | Engineered antibody-interferon mutant fusion molecules | |
| JP2014129395A5 (cg-RX-API-DMAC10.html) | ||
| JP2003528155A5 (cg-RX-API-DMAC10.html) | ||
| Campos et al. | Lactococcus lactis as an interleukin delivery system for prophylaxis and treatment of inflammatory and autoimmune diseases | |
| Antonelli et al. | Development of antibodies to interferon beta in patients: technical and biological aspects. | |
| JP2008527988A5 (cg-RX-API-DMAC10.html) | ||
| CN102380091A (zh) | 白介素-22在治疗病毒性肝炎中的应用 | |
| NO345071B1 (no) | Farmasøytisk preparat og anvendelse derav | |
| CN103110939A (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| WO2007063421A3 (en) | Compositions and methods relating to treatment of cancer and infectious diseases | |
| JP2010538619A5 (cg-RX-API-DMAC10.html) | ||
| JP2010508857A5 (cg-RX-API-DMAC10.html) | ||
| Trefzer et al. | Cytokine and anticytokine therapy in dermatology | |
| JP2002512013A (ja) | ケモカインを使用することによる遺伝的免疫に対する免疫応答の増強 | |
| DE50110752D1 (de) | Pneumovirus ns proteine antagonisieren die interferon (ifn) antwort | |
| JP2005526520A5 (cg-RX-API-DMAC10.html) | ||
| JP2008546672A5 (cg-RX-API-DMAC10.html) | ||
| RU2008100307A (ru) | Применение цитокина из семейства интерлейкина-6 для получения композиции для комбинированного введения с интерфероном-альфа |